Consistently, alanine mutations at E 6.53b decreased retatrutide-induced cAMP signaling potency by 3.6-fold for GLP-1R, 1.6-fold for GIPR and 8.3-fold for GCGR, while at E/D 7.42b , potency decreased by 71.6-fold for GIPR and 5.8-fold for GCGR (Fig
GLP-1 (semaglutide) acts on the brain to reduce feelings of hunger and increase feelings of fullness
In some cases, side effects diminish over time, allowing the body to adapt
KEY TAKEAWAYS PCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction 70 million women globally are affected during reproductive years, with 70% remaining undiagnosed The condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problems Treatment should focus on metabolic health rather than weight loss or ovarian interventions The name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver disease NOTABLE QUOTE "Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever
